345 PARK AVENUE SOUTH, NEW YORK, NY
Investor Presentation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Jose Manuel Otero Appointed Chief Operating Officer at Lexeo Therapeutics
Reports Third Quarter 2025 Financial Results and Operational Highlights
Announces Pricing of Public Offering and Concurrent Private Placement
Reports Second Quarter 2025 Financial Results and Operational Highlights
FY 2025
Q3
Q2
Amended Quarterly Report
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Free Writing Prospectus